Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The .0075 seller was finally cleaned out eod...
nice dump !
L2 shows a lower ask, lower bid, and volume that is better than usual.
Could be CCEL again selling, but earlier there were 1.8 ml for sale @ .0075....
jmo...
What do you mean Myth?
Could be either in your dreams...OR....after all the cash is paid out
.0081 with news !
MaryMary158..did you file the complaint?? I would love to help you file with braindead sandberg. Any good word with the complaint.
GL Longs
Over and out is OK by me.
GL Longs
With Red Oak holding 30% of the OS, it would take CCEL and a good number of larger shareholders to turn the votes against Red Oak imo.
If that would " benefit " current shareholders, that's a million dollar question. Most just want to get this over with imo, whether they like what Red Oak and the BOD has done or not.
If they don't, all they need to do is vote N0
Proposal 1: To approve the election of David Sandberg, Adrian Pertierra, Timothy McGrath and Anthony Snow as directors of the Company (the “Director Election Proposal”).
Proposal 2: To consider and vote upon a proposal to approve the voluntary dissolution and liquidation of the Company (the “Dissolution”) pursuant to a Plan of Dissolution in substantially the form attached to the accompanying proxy statement as Appendix A (such plan, the “Plan of Dissolution”, and such proposal, the “Dissolution Proposal”).
Proposal 3: To ratify the appointment of RBSM LLP as the Company’s independent registered certified public accounting firm for the fiscal year ending December 31, 2020 (the “Ratification Proposal”).
Proposal 4: To approve (on an advisory basis) the Company’s executive compensation (the “Say-on-Pay Proposal”).
Proposal 5: To grant discretionary authority to the Board to adjourn the Annual Meeting, even if a quorum is present, to solicit additional proxies in the event that there are insufficient shares present in person or by proxy voting in favor of the Dissolution pursuant to the Plan of Dissolution (such proposal, the “Adjournment Proposal”).
I forgot how it works, but shareholders can use Red Oak & CCEL share votes somehow to benefit us. I am riding this for first divi just to see what sandberg as a Hedge Fund guy will be like. Snow Job in lost in space.
GL Longs
Let me say it this way. I referred to the .0023 as the final payout, I meant second payout. This was in a question about where you said the .0023 that is released on may 17 and there's a nice bag of $$$ left after that .
After reading more I see it doesn't say in the filing its a final payout, I was saying final as a figure of speech thinking a second payout after the first payout of .0048
I didn't say you said it. I'm saying I referred in a question to where you said the .0023 that is released on may 17 as the final payout.
Where did I say " final " payout ?
Best to show me the post where I said that, then I can reply...
thanks !
I was referring to what you said about the .0023 that is released on May 17th as the "final" payout
CCEL filed another Form 4 that we missed, selling 2/19 and 2/20
https://www.sec.gov/Archives/edgar/data/862692/000089924320005499/xslF345X03/doc4.xml
Two years and he never gave us a penny. Why does he really want to keep the 2.2M ???
GL Longs
never happen.....the only one's that have any clout would be the CCEL boys, and they seem content to ride it out.
The vote will most likely confirm that, If ALL shareholders banded together things could be changed, but I highly doubt it.
Red Oak should get a lawsuit and I hope sandberg goes to JAIL.
GL Longs
I found this interesting....
Contingent Liabilities; Reserves (Page 31)
In connection with the Company’s dissolution, the Company is required by Florida law to pay or provide for payment of all of its liabilities and obligations, including making reasonable provision for the payment of contingent obligations. Following the effective date of the filing of the Articles of Dissolution with the Florida Secretary of State, the Company will pay all expenses and other known liabilities and maintain a reserve, consisting of cash or other assets, that the Company believes will be adequate for the satisfaction of all of its current contingent or conditional claims and liabilities. The Company may also take other steps to provide for the satisfaction of the reasonably estimated amount of such liabilities, including possibly seeking to acquire insurance coverage with respect to certain contingent liabilities. The Company currently estimates that it will maintain an initial cash reserve of approximately $2.2 million for unknown, contingent and/or conditional liabilities. In addition, the Company may use all or a portion of the net proceeds of any Potential Additional Proceeds it may receive in the future to satisfy any such liabilities. From time to time, the Company may distribute to its Shareholders on a pro rata basis any portions of the reserve that the Company deems to no longer be required. In the event the Company fails to create an adequate reserve for the payment of its expenses and liabilities and amounts have been distributed to the Shareholders under the Plan of Dissolution, creditors of the Company may be able to pursue claims against the Company’s Shareholders directly to an extent they have claims co-extensive with such Shareholders’ receipt of liquidating distributions. See “Risk Factors to be Considered by Stockholders in Deciding whether to Approve the Plan of Dissolution—If the Company fails to create an adequate reserve for payment of its expenses and liabilities, each Shareholder receiving liquidating distributions could be held liable for payment to the Company’s creditors of his, her or its pro rata share of amounts owed to creditors in excess of the reserve, up to the amount actually distributed to such Shareholder in connection with the Dissolution.”
As previously announced, following the receipt of shareholder approval on May 17, 2018, the Company sold substantially all of its operating assets (such sale, the “Transaction”) to California Cryobank Stem Cell Services LLC, a California limited liability company, pursuant to that certain Asset Purchase Agreement dated as of February 6, 2018 (the “Asset Purchase Agreement”). In light of the Company’s successful consummation of the Transaction and its desire to cease operations and distribute a substantial portion of the net proceeds from the Transaction, the Company’s Board of Directors (the “Board”) recommends that the Company wind down its operations.
The Board is therefore soliciting your approval of the following proposals at the Annual Meeting:
Proposal 1: To approve the election of David Sandberg, Adrian Pertierra, Timothy McGrath and Anthony Snow as directors of the Company.
Proposal 2: To consider and vote upon a proposal to approve the voluntary dissolution and liquidation of the Company (the “Dissolution”) pursuant to a Plan of Dissolution in substantially the form attached to the accompanying proxy statement as Appendix A.
Proposal 3: To ratify the appointment of RBSM LLP as the Company’s independent registered certified public accounting firm for the fiscal year ending December 31, 2020.
Proposal 4: To approve (on an advisory basis) the Company’s executive compensation.
Proposal 5: To grant discretionary authority to the Board to adjourn the Annual Meeting, even if a quorum is present, to solicit additional proxies in the event that there are insufficient shares present in person or by proxy voting in favor of the Dissolution pursuant to the Plan of Dissolution.
After careful consideration of a number of factors, as described in the attached proxy statement, the Board has unanimously determined that the Dissolution is advisable, fair to and in the best interests of the Company and its shareholders.
The Board unanimously recommends that you vote “FOR” each of the proposals in the proxy statement and “FOR” the election of each of the director nominees.
https://www.sec.gov/Archives/edgar/data/1289496/000165495420003135/cbai_pre14a.htm
Looks like the MBA is back with news from sandberg.
This I believe in.......
*****Don't think so ! More like .0001 with news
I don't see a " final " payout in May A77....
CBAI will continue to trade on the pinks...
gl !
Thanks Myth. Will the shares after the final payout in May trade on the pink sheets?
After reading this over again, and not able to get a clarification from Snow, it appears to me that the .0048 initial payout they mention does NOT include the .0023 that is released on May 17th ( 3 ml escrow ).
That takes it to .0071.....there's a nice bag of $$$ left after that...
Note 11. Subsequent Events
On February 11, 2020, the Company’s Board of Directors approved a Plan of Dissolution of the Company (the “Plan of Dissolution”) for the orderly liquidation and wind-up of the Company (the “Dissolution”). The Plan and the Dissolution are contingent on approval of the Plan by the Company’s shareholders. If the Company’s shareholders approve the Plan, the Company presently intends to make an initial distribution of at least $0.0048 per share of common stock as promptly as reasonably possible thereafter. Based on the information currently available to it, the Company is unable to estimate the aggregate amount which will ultimately be distributed to its shareholders. The actual amounts of any liquidating distributions may vary substantially, depending on, among other things, whether the Company becomes subject to any additional liabilities or claims, including potential claims for indemnification relating to sales of the Company’s assets, whether the Company incurs unexpected or greater than expected losses with respect to contingent liabilities, the extent to which the Company is able to monetize any remaining non-cash assets and any future amounts received by the Company in connection with, among other things, all future amounts received by the Company, including the amount of asset sale proceeds to be released from escrow upon the termination of the escrow in May 2020.
Sorry, posted on the wrong board.
CBAI has an estimated .0105 per share in cash after selling all assets and recently announcing it will have SHs vote in Q2 to liquidate. Closed today at .0076 so a great arbitrage opportunity which should provide downside protection in this free fall market. Company controlled by Red Oak, a reputable hedge fund which came in as White Knight to rebuff low ball takeover and then sold all assets at much higher price. I'm long as it seems a sensible play in this market.
You guys ready for $0.0003s and such?
2 minutes of actual DD will inform anyone that CBAI sold all of it's assets, it will be 2 years on 5/17 that this happened.
https://www.accesswire.com/500182/Cord-Blood-America-Inc-Announces-Closing-of-Sale-of-Business
As far as News taking this to .10, it's never going to happen.
Here's all the filings, what will happen someday is that the co will pay out what cash is left to the shareholders of record. It's that simple.
https://www.sec.gov/cgi-bin/browse-edgar?company=cord+blood+america&owner=exclude&action=getcompany
What's with today's hidden 911 code? Thanks!!!!!
Followers
|
387
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
105534
|
Created
|
03/15/05
|
Type
|
Free
|
Moderators |
Cord Blood America, Inc.(CBAI), through its wholly owned subsidiary CorCell Companies, Inc., is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy.
The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.
There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases.
CBAI offers extensive experience, with over 16 years in the cord blood banking industry, a proven processing model, technology and all the assistance our business to business clients need to grow their cord blood banking company without the additional cost of operating their own laboratory. CBAI is licensed in New Jersey, New York, California and Maryland and registered with the FDA. They are also a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.
Cord Blood America's state of the art laboratory is located minutes from McCarran International Airport in Las Vegas, NV; with approximately 3,300 inbound flights per week they are able to receive customer samples 24/7/365. Cord Blood America is a fully licensed cord blood bank that has processed more than 27,000 cord blood units since first opening in 1996. The 17,000-square-foot facility is equipped with the most advanced processing and storage technologies. The facility is under 24 hour surveillance with stringent restricted access protocols your client's cord blood unit will be kept at the correct temperature at all times thanks to our 24 hour monitoring system.The Tissue Bank Director had more than 25 years of experience in the stem cell field. A staff of highly experienced health professionals and technicians, working under the guidance and expertise of CBAI's Scientific/Medical Advisory Panel of industry leaders, offers both technical skill and unparalleled leadership. This unique combination of talents ensures that the laboratory remains on the cutting-edge of new cord blood advances, while guarenteeing the safety, integrity and viability of your customer's cord blood unit.
| ? | Total revenue for the second quarter was $0.75 million, a decrease of 5.9% from total revenue of $0.79 million for the second quarter 2016. |
| | |
| ? | Recurring storage revenue for the second quarter 2017 was $0.66 million, a decrease of 4.4% from recurring storage revenue of $0.69 million for the second quarter 2016. |
| | |
| ? | EBITDA for the second quarter 2017 was $0.20 million, an increase of 151.9% from EBITDA of $0.08 million for the second quarter 2016. |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |